The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. - Wikidata - awgldk - TriplyDB

The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer.

The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer.

http://www.wikidata.org/entity/Q41566518

about

Galeterone for the treatment of advanced prostate cancer: the evidence to date Technical challenges in the isolation and analysis of circulating tumor cells Single-Cell Analysis of Circulating Tumor Cells as a Window into Tumor Heterogeneity Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival.Activation of GRP/GRP-R signaling contributes to castration-resistant prostate cancer progression.Liquid biopsy: ready to guide therapy in advanced prostate cancer?The Cohesive Metastasis Phenotype in Human Prostate Cancer.The molecular underpinnings of prostate cancer: impacts on management and pathology practice.Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer.Emerging Variants of Castration-Resistant Prostate Cancer.Extracellular vesicles for liquid biopsy in prostate cancer: where are we and where are we headed?Prostate Cancer Stem Cell Markers Drive Progression, Therapeutic Resistance, and Bone Metastasis.Recent advances in circulating tumor cells and cell-free DNA in metastatic prostate cancer: a review.Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer.Androgen receptor expression on circulating tumor cells in metastatic breast cancer.Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) Workshop 2016: Scientific Opportunities and Logistics for Cancer Clinical Trial Incorporation.Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC).Synaptophysin expression on circulating tumor cells in patients with castration resistant prostate cancer undergoing treatment with abiraterone acetate or enzalutamide.CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer.Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.Understanding cancer lineage plasticity: reversing therapeutic resistance in metastatic prostate cancer.Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer.Label-free isolation of prostate circulating tumor cells using Vortex microfluidic technology.

P2860

Q26739887-22353A80-0033-4E37-BCD8-01914A1A3950 Q26741646-A7ABD72A-43BB-4BC8-BCDA-090E37A991D0 Q33883227-3CFE7D28-529D-49EA-A3A1-1672E9D90611 Q36356608-56BD8A55-B6E9-4A15-8BCE-3511456841AD Q37641718-2490EFEC-1F39-4C2C-B451-96E6782B73A1 Q38840458-A3FE09EC-5A03-4EF8-8533-172A869BDA30 Q38966462-85FE883B-3646-4082-84DE-0BEB5A68BA0C Q38983790-4D9AA8BF-4B21-42E4-B499-43658C50DEE5 Q39016544-FCC614FD-348D-4254-BB37-8980F40C4182 Q39210257-AF0A3144-5FBC-4FD1-B155-1DCDC0B14134 Q39218490-562A3687-B33F-4026-87A5-2A85DEFB60A1 Q39424549-BFA09ADB-0C3E-4ACF-BA1E-8BE3ACD3BA6F Q39454057-F1D0F6CF-AA32-4050-A38E-01B232CC14E4 Q40496979-51F80BA7-D0C3-492F-8B35-DDFB0603D2E2 Q42366191-6F977E30-9D1F-4D5B-9976-7A9AF24735B6 Q42390872-5FCE217C-1B7A-48F3-965B-C5A760664177 Q47269802-1E99A630-6F79-4115-A1EB-B8247D37C478 Q47561890-1FB1F1B6-4633-4147-80CF-A3A52B70A586 Q47740995-408222A1-8768-4CEE-8D0C-F5D6008B79DD Q51465026-38F96E35-BC0E-4185-92B9-CCCF55F5147D Q53741551-82FB3845-4420-4A63-AC16-59A07D4AFE69 Q55343494-A897782B-9C05-4EEB-B44D-FB2A5C986D0F Q55394255-64A1C5FE-6CE5-482A-9EEE-9DCB0DCD7A06

P2860

The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer.

http://www.wikidata.org/entity/Q41566518

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

The Initial Detection and Part ...... euroendocrine Prostate Cancer.

@en

type

label

The Initial Detection and Part ...... euroendocrine Prostate Cancer.

@en

prefLabel

The Initial Detection and Part ...... euroendocrine Prostate Cancer.

@en

P1433

Q41566518-02795597-C844-432A-8C89-5387EAA985A5

P1476

Q41566518-9DF7ACD9-345C-4123-9A35-1E557E94755D

P2093

Q41566518-236287ED-38DA-41BA-BC81-CD5398CACCE4

Q41566518-2773CD2D-C368-43FF-8C88-62A61FA50CA8

Q41566518-279A1066-DCF8-445B-A32E-81C3B0135406

Q41566518-3DA7EA88-56A6-40B8-A6BA-F1455CB67380

Q41566518-51E5A8B0-9B9F-4CE9-BFA1-E84DD8042264

Q41566518-6F850503-D5AD-44B5-932E-7FB5C6CB80EC

Q41566518-795FD5BC-9CCE-473C-B4F1-1FBE76ABF7C4

Q41566518-7B4D21AC-18E3-471A-A386-29D7C7AA81B4

Q41566518-82F2DFDF-8B95-4A7E-9DE4-FE8315F032C7

Q41566518-8965F2F5-8980-47DA-8B2F-48E300004ADC

P2860

Q41566518-06BE6DAC-D835-4209-9C73-06406EE47C5A

Q41566518-1C1A65A3-FF2E-46E4-A43E-8619B01B2968

Q41566518-1D2F5851-4E80-4A2C-B13A-1B780A654455

Q41566518-2147CC3B-4375-4D2A-8290-7AD9A1495A01

Q41566518-221CAEFE-5FC0-4298-932A-A7D5ED016FDE

Q41566518-2441624C-169E-4A77-8C2F-0F04D04073E3

Q41566518-2C68FF16-9D3B-42EE-8487-020C70CDDAB2

Q41566518-31C398B1-1493-46F0-89C1-ED666A69A5B6

Q41566518-4395B038-BFB4-459A-AB33-75AFFF462823

Q41566518-46CF9DCB-ACF6-45D7-9D7C-ABCB16262BE1

P304

Q41566518-9937AAC8-000B-4A59-9E88-4CC1FF099070

P31

Q41566518-0F958F94-66DE-4406-97D4-9FE6EDDAADCE

P356

Q41566518-45B8E251-4FC1-4E4A-A10C-7EDBE4458299

P407

Q41566518-CFBF7D0F-7A3D-4FAC-8AFD-7FA0DFDE9368

P433

Q41566518-76B5924D-DA2D-466A-987F-694E7B609D59

P478

Q41566518-3AE90E22-F97B-481A-AAFB-8E87495F1524

P577

Q41566518-DC9B133D-9EBC-4865-A5FD-EF64945F49F9

P698

Q41566518-F3D448FD-DEC4-420F-B978-F8A67C20EAA9

P932

Q41566518-3D274574-9F12-484E-8661-801AE3C970F5

P356

1078-0432.CCR-15-0137

P1433

Clinical Cancer Research

P1476

The Initial Detection and Part ...... euroendocrine Prostate Cancer.

@en

P2093

Adam Jendrisak

http://www.w3.org/2001/XMLSchema#string

David M Nanus

http://www.w3.org/2001/XMLSchema#string

Dena Marrinucci

http://www.w3.org/2001/XMLSchema#string

Himisha Beltran

http://www.w3.org/2001/XMLSchema#string

Howard I Scher

http://www.w3.org/2001/XMLSchema#string

Jessica Louw

http://www.w3.org/2001/XMLSchema#string

Juan Miguel Mosquera

http://www.w3.org/2001/XMLSchema#string

Mark Landers

http://www.w3.org/2001/XMLSchema#string

Myriam Kossai

http://www.w3.org/2001/XMLSchema#string

Nicole A Schreiber

http://www.w3.org/2001/XMLSchema#string

P2860

Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers

Neuroendocrine (small-cell) carcinomas: why they teach us essential lessons about prostate cancer

Cancer statistics, 2015

Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition

Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance

High speed detection of circulating tumor cells.

Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate.

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Aggressive variants of castration-resistant prostate cancer

The epigenetics of epithelial-mesenchymal plasticity in cancer.

P304

1510-1519

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-15-0137

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26671992

http://www.w3.org/2001/XMLSchema#string

P932

4990782

http://www.w3.org/2001/XMLSchema#string